NCT03995017进行中（未招募）1 期
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
- 试验地点
- 8
- 主要终点
- Recommended Phase 2 Dose (RP2D)
研究概览
简要总结
The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of care chemotherapy. The goal is to demonstrate that Rucaparib plus Ramucirumab with or without Nivolumab has a higher response rate than what has been reported for Ramucirumab in previously treated patients. Trial will be a phase 1/2 trial. The Phase 1 portion will determine the recommended Phase 2 treatment dose for the combination of Rucaparib plus Ramucirumab and Nivolumab and enroll approximately 6-9 participants. The Phase 2 portion of the study will involve 52 participants allocated between two treatment groups comparing Rucaparib plus Ramucirumab with or without Nivolumab. The participants will be selected based on the results of a screening HRD gene panel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Half of the study population in phase 2 must have a deleterious tumor alteration in at least one protocol specified gene
- •Gastric or gastroesophageal junction adenocarcinoma
- •Advanced stage 4 or locally unresectable stage 3 disease
- •Must have measurable disease
- •Must consent to have a biopsy if archival tissue is not available or not enough for molecular testing
- •Must show evidence of progression or intolerance to at least one previous standard of care systemic therapy (not more than 2 lines of prior therapy)
- •Patients with human epidermal growth factor receptor 2 (HER2) positive disease must show progression on prior HER2 targeted therapy
- •Toxicities related to prior treatment should be recovered to baseline or less than grade 2 according to CTCAE
- •Adequate organ and marrow function
- •Absence of active autoimmune disease that has required systemic treatment in the past 2 years
- •Absence of conditions requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration. 10mg or less of prednisone or equivalent is acceptable
- •Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients
- •Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception prior to study entry, for the duration of study participation, and for 6 months following completion of therapy
- •Men of child-bearing potential must not father a child or donate sperm while on this study and for 7 months after their last study treatment
排除标准
- •Prior treatment with a programmed cell death protein 1 (PD1) or programmed death- ligand 1 (PD-L1) inhibitors
- •Prior treatment with poly-(ADP-Ribose)polymerase (PARP)
- •Patients with microsatellite instability (MSI) high or mismatch repair (MMR) deficient tumors
- •Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose
- •Evidence of active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction
- •Inability to swallow tablets
- •Uncontrollable ascites or pleural effusion
- •Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation
- •Clinically significant hematuria, hematemesis, or hemoptysis, or other history of significant bleeding within 12 weeks
- •Lesions invading any major blood vessels
- •Receipt of the last dose of anticancer therapy less than 28 days prior to the first dose of study drug
- •Major surgery within 8 weeks before first dose of study treatment
- •History of allogenic organ transplantation
- •Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. Patients with a past or resolved hepatitis B virus (HBV) infection are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for hepatitis C virus (HCV) RNA
- •Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or serious chronic gastrointestinal conditions
- •Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment
- •Prolonged baseline QT interval corrected for heart rate greater than 470 ms
- •Brain metastases or spinal cord compression. Patients whose brain metastases have been treated may participate provided they show radiographic stability
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- •Current or anticipated use of other investigational agents while participating in this study
- •History of another primary malignancy except for:
- •Malignancy treated with curative intent and with no known active disease before the first dose of investigational product (IP) and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease
- •Psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant or breast feeding
研究组 & 干预措施
Safety Lead In
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients
- 1 cycle= 28 days
干预措施: Rucaparib (Drug)
Safety Lead In
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients
- 1 cycle= 28 days
干预措施: Ramucirumab (Drug)
Safety Lead In
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- One dose level decrease of Rucaparib will be planned if toxicity develops in the first 6 patients
- 1 cycle= 28 days
干预措施: Nivolumab (Drug)
Cohort A
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- 1 cycle= 28 days
干预措施: Rucaparib (Drug)
Cohort A
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- 1 cycle= 28 days
干预措施: Ramucirumab (Drug)
Cohort A
Experimental
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Nivolumab 480 milligrams intravenous every 4 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- 1 cycle= 28 days
干预措施: Nivolumab (Drug)
Cohort B
Active Comparator
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- 1 cycle= 28 days
干预措施: Rucaparib (Drug)
Cohort B
Active Comparator
- Rucaparib 600 milligrams twice daily
- Ramucirumab 8 milligrams per kilogram intravenous every 2 weeks
- Treatment will continue until disease progression, unacceptable toxicity or the patient desires to discontinue this therapy
- 1 cycle= 28 days
干预措施: Ramucirumab (Drug)
结局指标
主要结局
Recommended Phase 2 Dose (RP2D)
时间窗: Up to 28 days
Defined as the highest dose studied for which the observed incidence of dose limiting toxicities (DLT) is less than 33%. DLTs will be measured per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Overall Response Rate (ORR)
时间窗: up to 12 months
Defined as the proportion of participants with overall response to therapy. Overall response is defined as the best response recorded, (including Complete Response (CR) and Partial Response (PR)), from the start of the treatment until the end of treatment. ORR will be measured per the Modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
次要结局
- Number of participants with treatment related adverse events (TRAEs)(Up to 12 months)
- Progression free survival (PFS)(Up to 12 months)
- Overall survival (OS)(Up to 12 months)
- Overall Benefit Rate (OBR)(Up to 12 months)
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic CorrelatesTumorsGastric CancerEsophageal CancerNCT00130936AHS Cancer Control Alberta50
Unknown
2 期
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerGastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)NCT05246982Shanghai Henlius Biotech40
终止
2 期
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based TherapyPancreatic CancerNCT03140670Abramson Cancer Center at Penn Medicine46
招募中
3 期
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCGastric CancerNCT04342910Jiangsu HengRui Medicine Co., Ltd.550
已完成
3 期
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT02370498Merck Sharp & Dohme LLC592